XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB

Across many cancer types in adults, upregulation of the nuclear-to-cytoplasmic transport protein Exportin-1 (XPO1) correlates with poor outcome and responsiveness to selinexor, an FDA-approved XPO1 inhibitor. Similar data are emerging in childhood cancers, for which selinexor is being evaluated in e...

Full description

Bibliographic Details
Main Authors: Basia Galinski, Marcus Luxemburg, Yosef Landesman, Bruce Pawel, Katherine J. Johnson, Stephen R. Master, Kevin W. Freeman, David M. Loeb, Jean M. Hébert, Daniel A. Weiser
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Translational Oncology
Subjects:
Neuroblastoma
Exportin-1
Selinexor
Bortezomib
IkB
NF-kB
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321001066

Similar Items

Similar Items